Citius Oncology, Inc. Common Stock and TuHURA Biosciences, Inc. Common Stock
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
Open CTOR dashboard ↗TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-specific antibody-peptide conjugates and antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.
Open HURA dashboard ↗You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.
Sign in →